Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Financial Officer

Chief Scientific Officer

Chief Business & Strat Officer

VP/Chief Accounting Officer

Chief Technical Officer

General Counsel

Chief Executive Officer

Chief Commercial Officer

Chief People Officer

Chief Development Officer

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization ...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-18	Premium	gifted	Premium	Premium	Premium	Chief Financial Officer
2024-04-18	Premium	gifted	Premium	Premium	Premium	Chief Financial Officer
2024-04-12	Premium	acquired	Premium	Premium	Premium	-
2024-04-08	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2024-04-08	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2024-04-01	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-04-01	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-03-19	Premium	sold	Premium	Premium	Premium	-
2024-03-18	Premium	sold	Premium	Premium	Premium	Chief Business & Strat Officer
2024-03-15	Premium	sold	Premium	Premium	Premium	VP/Chief Accounting Officer
2024-03-13	Premium	sold	Premium	Premium	Premium	Chief Technical Officer
2024-03-08	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2024-03-08	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2024-03-06	Premium	acquired	Premium	Premium	Premium	General Counsel
2024-03-01	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-03-01	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-02-12	Premium	sold	Premium	Premium	Premium	Chief Commercial Officer
2024-02-12	Premium	sold	Premium	Premium	Premium	Chief Business & Strat Officer
2024-02-12	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2024-02-12	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-02-12	Premium	sold	Premium	Premium	Premium	General Counsel
2024-02-12	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-01-30	Premium	sold	Premium	Premium	Premium	Chief People Officer

APLS - Apellis Pharmaceuticals Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for APLS